Flexible CGP Analysis Without Compromise: MSK-IMPACT® Flex Powered with SOPHiA DDM™

Traditional genomic analysis often requires sequential testing or a “one-size-fits-all” comprehensive genomic profiling (CGP) panel, leading to time-consuming workflows and increased costs. The new MSK-IMPACT® Flex powered with SOPHiA DDM™ solution offers an agile and modular approach to CGP, enabling labs to achieve flexible, cost-efficient, and scalable analysis of solid tumors.

Built on the expert-designed MSK-IMPACT® assay and combined with the adaptive analytics of the SOPHiA DDM™ Platform, this end-to-end solution delivers high-resolution profiling of complex biomarkers from DNA and RNA. Labs can tailor biomarker coverage to each sample, with the flexibility to add RNA and homologous recombination deficiency (HRD) analysis as needed.

By attending this session, you will:

• Learn how a modular CGP approach can improve lab efficiency and cost-effectiveness.

• Explore the breadth of biomarker detection, including SNVs, Indels, CNVs (whole gene amplifications/deletions and exon-level), gene expression, partner-agnostic fusions, exon-skipping events, TMB, MSI and HRD.

• Gain insights into robust analytical performance results powered by SOPHiA DDM™’s advanced algorithms and noise-reduction technology.